专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20200325153A1 Macrocyclic MCL-1 Inhibitors and Methods of Use 审中-公开
公开(公告)号：US20200325153A1
公开(公告)日：2020-10-15
申请号：US16872279
申请日：2020-05-11
申请人： AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
发明人： Andrew S. Judd , Aaron R. Kunzer , Chunqiu Lai , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Jesse A. Teske , Anthony Mastracchio , Xilu Wang , Cheng Ji , Michael D. Wendt , Xiaohong Song , George A. Doherty , Katja Jantos , Wilfried Braje , Andreas Kling , Frauke Pohlki , Thomas D. Penning
IPC分类号： C07D495/16 , C07D495/18 , A61K45/06 , C07D495/22 , C07D491/18 , A61K31/519 , C07D491/22 , A61P35/00 , A61P35/02
摘要： The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

2. 发明申请

US20190144465A1 Macrocyclic MCL-1 inhibitors and methods of use 审中-公开
公开(公告)号：US20190144465A1
公开(公告)日：2019-05-16
申请号：US15998789
申请日：2018-08-15
申请人： AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
发明人： Andrew S. Judd , Aaron R. Kunzer , Chunqiu Lai , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Jesse A. Teske , Anthony Mastracchio , Xilu Wang , Cheng Ji , Michael D. Wendt , Xiaohong Song , George A. Doherty , Katja Jantos , Wilfried Braje , Andreas Kling , Frauke Pohlki , Thomas D. Penning
IPC分类号： C07D495/16 , A61P35/02
摘要： The present disclosure provides for compounds of formula (I) wherein A2, A3, A4, A6, A7, A8, R15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of formula (I).

3. 发明授权

US09840495B2 Oxindole derivatives carrying a piperidyl-substituted azetidinyl substituent and use thereof for treating vasopressine-related diseases 有权
公开(公告)号：US09840495B2
公开(公告)日：2017-12-12
申请号：US15106670
申请日：2014-12-19
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： Hervé Geneste , Wilfried Hornberger , Charles W. Hutchins , Katja Jantos , Andreas Kling , Loic Laplanche , Marcel Van Gaalen
IPC分类号： A01N43/00 , A61K31/00 , C07D401/14 , C07D401/04 , C07B59/00 , C07D405/14 , C07D491/107
CPC分类号： C07D401/14 , C07B59/002 , C07B2200/05 , C07D401/04 , C07D405/14 , C07D491/107
摘要： The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for treatment of vasopressin-related disorders.

4. 发明授权

US09527811B2 Carboxamide compounds and their use as calpain inhibitors 有权
公开(公告)号：US09527811B2
公开(公告)日：2016-12-27
申请号：US14570996
申请日：2014-12-15
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： Helmut Mack , Andreas Kling , Katja Jantos , Achim Moeller , Wilfried Hornberger , Charles W. Hutchins
IPC分类号： C07D207/26 , C07D207/28 , C07D401/12 , C07D233/34 , C07D239/10 , C07D207/22 , C07D211/78 , C07D211/76 , C07D233/32 , C07D275/03 , C07D401/06 , C07D405/12 , C07D409/12 , C07D417/12 , C07D213/81
CPC分类号： C07D207/22 , C07D207/26 , C07D207/28 , C07D211/76 , C07D211/78 , C07D213/81 , C07D233/32 , C07D233/34 , C07D239/10 , C07D275/03 , C07D401/06 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12
摘要： The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.The carboxamide compounds are compounds of the general formula I in which R1, R2, R3a, R3b, R4, Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib in which R1, r, R2b, R3a, R3b, R4, Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y is a moiety CH2—CH2, CH2—CH2—CH2, N(Ry#)—CH2, N(Ry#)—CH2—CH2 or CH═CH—CH═, each optionally having 1 or 2H-atoms replaced with identical or different radicals Ry, wherein Ry and Ry# have the meanings mentioned in the claims.

5. 发明申请

US20160168135A1 OXINDOLE DERIVATIVES CARRYING AN OXETANE SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES 审中-公开
标题翻译：携带OXETANE取代物的OXINDOLE衍生物及其用于治疗相关疾病的用途
公开(公告)号：US20160168135A1
公开(公告)日：2016-06-16
申请号：US15050264
申请日：2016-02-22
申请人： AbbVie Deutschland GmbH & Co. KG
发明人： Katja Jantos , Wilfried Braje , Hervé Geneste , Andreas Kling , Liliane Unger , Berthold Behl , Marcel van Gaalen , Wilfried Hornberger , Loic Laplanche , Silke Weber
IPC分类号： C07D405/14 , C07D487/08
CPC分类号： C07D405/14 , C07D487/08
摘要： The present invention relates to novel substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders.
摘要翻译：本发明涉及新型取代的羟基吲哚衍生物，包含它们的药物组合物及其用于治疗加压素相关病症的用途。

6. 发明申请

US20220259226A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE 有权
公开(公告)号：US20220259226A1
公开(公告)日：2022-08-18
申请号：US17660355
申请日：2022-04-22
申请人： AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
发明人： Wilfried Braje , George Doherty , Katja Jantos , Cheng Ji , Andrew Judd , Aaron Kunzer , Anthony Mastracchio , Xiaohong Song , Andrew Souers , Gerard Sullivan , Zhi-Fu Tao , Chunqiu Lai , Jesse Teske , Michael Wendt , Patrick Brady , Xilu Wang , Thomas Penning , Yujia Dai , Jane Gong , Roberto Risi , Yiyun Yu , Guidong Zhu
IPC分类号： C07D498/18 , A61P35/00 , C07D519/00 , C07D495/18 , C07D495/16 , A61K31/519 , C07D491/16 , C07D498/16
摘要： The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

7. 发明申请

US20200010480A1 Macrocyclic MCL-1 Inhibitors and Methods of Use 审中-公开
公开(公告)号：US20200010480A1
公开(公告)日：2020-01-09
申请号：US16575114
申请日：2019-09-18
申请人： AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
发明人： Patrick B. Brady , Wilfried Braje , Yujia Dai , George A. Doherty , Jane Gong , Katja Jantos , Cheng Ji , Andrew S. Judd , Aaron R. Kunzer , Chunqiu Lai , Anthony Mastracchio , Roberto M. Risi , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Jesse A. Teske , Xilu Wang , Michael D. Wendt , Yiyun Yu , Guidong Zhu , Thomas D. Penning
IPC分类号： C07D498/18 , A61P35/00 , C07D519/00 , C07D495/18 , C07D495/16
摘要： The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

8. 发明申请

US20190055264A1 Macrocyclic MCL-1 inhibitors and methods of use 审中-公开
公开(公告)号：US20190055264A1
公开(公告)日：2019-02-21
申请号：US15998688
申请日：2018-08-15
申请人： AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
发明人： Patrick B. Brady , Wilfried Braje , Yujia Dai , George A. Doherty , Jane Gong , Katja Jantos , Cheng Ji , Andrew S. Judd , Aaron R. Kunzer , Chunqiu Lai , Anthony Mastracchio , Roberto M. Risi , Xiaohong Song , Andrew J. Souers , Gerard M. Sullivan , Zhi-Fu Tao , Jesse A. Teske , Xilu Wang , Michael D. Wendt , Yiyun Yu , Guidong Zhu , Thomas D. Penning
IPC分类号： C07D498/18 , C07D495/18 , C07D519/00 , A61P35/00
摘要： The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).

9. 发明授权

US09527856B2 Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases 有权
标题翻译：携带CO键螺旋取代基的羟吲哚化合物及其用于治疗加压素相关疾病的用途
公开(公告)号：US09527856B2
公开(公告)日：2016-12-27
申请号：US14713824
申请日：2015-05-15
申请人： AbbVie Deutschland GmbH & Co. KG
发明人： Wilfried Braje , Hervé Geneste , Wilfried Hornberger , Katja Jantos , Andreas Kling , Claudia Krack , Marcel Van Gaalen
IPC分类号： C07D471/10 , C07D295/135 , C07D305/08 , C07D401/14 , C07D487/10 , C07D209/40 , C07D213/64
CPC分类号： C07D487/10 , C07D209/40 , C07D213/64 , C07D295/135 , C07D305/08 , C07D401/14 , C07D471/10
摘要： The present invention relates to novel substituted oxindole derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising compounds I and their use for the treatment of vasopressin-related disorders.
摘要翻译：本发明涉及式I的新的取代的羟基吲哚衍生物，其中变量如权利要求和说明书所定义。本发明还涉及包含化合物I及其用于治疗加压素相关病症的用途的药物组合物。

10. 发明申请

US20150329551A1 OXINDOLE COMPOUNDS CARRYING A NITROGEN-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES 有权
标题翻译：携带氮离子螺旋体替代物的氧化合物及其用于治疗相关疾病的用途
公开(公告)号：US20150329551A1
公开(公告)日：2015-11-19
申请号：US14713909
申请日：2015-05-15
申请人： AbbVie Deutschland GmbH & Co. KG
发明人： Hervé Geneste , Wilfried Hornberger , Katja Jantos , Andreas Kling , Marcel Van Gaalen
IPC分类号： C07D487/10
CPC分类号： C07D471/10 , C07D295/135 , C07D305/08 , C07D487/10
摘要： The present invention relates to novel substituted oxindole derivatives of the formula I wherein A is a ring selected from phenyl and 6-membered hetaryl containing 1 or 2 nitrogen atoms as ring members, where ring A carries one substituent R6 and optionally one substituent R7; B is a ring selected from phenyl and a monocyclic or bicyclic heteroaromatic ring containing 1, 2 or 3 heteroatoms selected from O, N and S as ring members, where ring B may carry 1, 2 or 3 substituents R8; X1, X2, X3 and X4, independently of each other, are selected from —CH2—, —O—, —S(O)c—, —NH—, —C(O)—, —CH2CH2—, —CH2O—, —OCH2—, —S(O)cCH2—, —CH2S(O)c—, CH2NH—, —NHCH2—, —CH2C(O)— and C(O)CH2—; X5 is NH, CH2 or O; and wherein c, R1, R2, (R3)a, (R4)b, R5, R6, R7, and R8 are as defined in the claims. The present invention also relates to pharmaceutical compositions comprising the novel substituted oxindole derivatives of the formula I, and to their use for the treatment of vasopressin-related disorders
摘要翻译：本发明涉及式I的新的取代羟吲哚衍生物，其中A是选自苯基和含有1或2个氮原子作为环成员的6元杂芳基的环，其中环A携带一个取代基R6和任选的一个取代基R7; B是选自苯基和含有1,2或3个选自O，N和S的环成员的单环或双环杂芳族环的环，其中环B可以带有1,2或3个取代基R8; X1，X2，X3和X4彼此独立地选自-CH 2 - ， - O - ， - S（O）c - ， - NH - ， - C（O） - ， - CH 2 CH 2 - ，-OCH 2 - ， - S（O）cCH 2 - ， - CH 2 S（O）c - ，CH 2 NH - ， - NHCH 2 - ， - CH 2 C（O） - 和C（O） X 5是NH，CH 2或O; 并且其中c，R 1，R 2，（R 3）a，（R 4）b，R 5，R 6，R 7和R 8如权利要求中所定义。本发明还涉及包含式I的新型取代的羟吲哚衍生物的药物组合物及其用于治疗加压素相关疾病的用途

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式